ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1048

Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study

Jacqueline Lemmers1, Arjan van Caam2, Brigit Kersten2, Els Ende, van den2, Hanneke KNAAPEN2, Arie Dijk, van2, Wanda Hagmolen of ten Have2, Frank van den Hoogen2, Hans Koenen2, Sander van Leuven3, wynand Alkema4, Ruben Smeets2 and Madelon Vonk5, 1Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, 2Radboudumc, Nijmegen, Netherlands, 3Radboud University, Nijmegen, Netherlands, 4Hanze University, Groningen the Netherlands, Dept. Data Science for Life Sciences & Health, Groningen, Netherlands, 5Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), Biomarkers, cytokines, interstitial lung disease, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Systemic Sclerosis and Related Disorders – Clinical Poster I

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Pulmonary hypertension (PH) is one of the leading causes of death in Systemic Sclerosis (SSc). Early detection and treatment of PH in SSc is crucial. Nailfold capillaroscopy microscopy (NCM), vascular auto-antibodies AT1R and ETAR and several candidate-biomarkers have potential to serve as non-invasive tools to identify SSc patients at risk for developing PH. Here we explore the classifying potential of NCM characteristics and serum levels of selected candidate-biomarkers in a sample of SSc patients with and without different forms of PH.

Methods: 81 consecutive SSc patients were included; 40 with associated PH (SSc-PH) and 41 without PH (SSc-noPH). In each group quantitative and qualitative NCM characteristics, vascular auto-antibodies AT1R and ETAR and serum levels of 24 soluble serum factors were determined. For evaluation of NCM characteristics linear regression analysis accounting for age, sex and DLCO % predicted was used. Auto-antibodies and soluble serum factor levels were compared by two-sample t test with equal variances.

Results: No statistical significant differences were observed in quantitative or qualitative NCM characteristics, or vascular auto-antibody ETAR and AT1R titer between SSc-PH and SSc-noPH. In contrast, several serum levels of soluble factors differed between groups; Endostatin, sVCAM, VEGFD were increased, and CXCL4, sVEGFR2 and PDGF-AB/BB were decreased in SSc-PH. Random forest classification identified Endostatin and CXCL4 as most predictive classifiers to distinguish SSc-PH from SSc-noPH.

Conclusion: This study shows potential for several soluble serum factors to distinguish SSc-PH from SSc-noPH. We found no classifying potential for qualitative or quantitative NCM characteristics, or vascular autoantibodies.


Disclosures: J. Lemmers, None; A. van Caam, None; B. Kersten, None; E. Ende, van den, None; H. KNAAPEN, None; A. Dijk, van, Jannsen Pharmaceutical, Bayer; W. Hagmolen of ten Have, None; F. van den Hoogen, None; H. Koenen, None; S. van Leuven, None; w. Alkema, None; R. Smeets, None; M. Vonk, Boehringer Ingelheim, Ferrer, Galapagos, Janssen, Merck/MSD, Corbus, EUSTAR.

To cite this abstract in AMA style:

Lemmers J, van Caam A, Kersten B, Ende, van den E, KNAAPEN H, Dijk, van A, Hagmolen of ten Have W, van den Hoogen F, Koenen H, van Leuven S, Alkema w, Smeets R, Vonk M. Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/nailfold-capillaroscopy-and-candidate-biomarker-levels-in-systemic-sclerosis-associated-pulmonary-hypertension-profiling-of-non-invasive-markers-a-cross-sectional-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nailfold-capillaroscopy-and-candidate-biomarker-levels-in-systemic-sclerosis-associated-pulmonary-hypertension-profiling-of-non-invasive-markers-a-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology